Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M5940 | Rosiglitazone HCl | Rosiglitazone HCl is a hypoglycemic compound that stimulates insulin secretion by binding to PPAR receptors in fat cells. |
| M2748 | GW9662 | GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM, with at least 100 to 1000-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ. |
| M1880 | WY 14643 (Pirinixic Acid) | WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. |
| M2335 | ZLN005 | ZLN005 is a novel and potent small molecule PGC-1α transcriptional activator. |
| M5878 | Pioglitazone HCl | Pioglitazone HCl is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes. |
| M3283 | Pioglitazone | Pioglitazone (U 72107) is a selective peroxisome proliferator-activated receptor gamma stimulator. |
| M1894 | Rosiglitazone | Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor. |
| M2747 | GW7647 | GW7647 is a potent and highly selective PPARα agonist with EC50 of 6 nM. |
| M6723 | Fenofibrate | Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate inhibited cytochrome P450 subtype, with IC50 of 0.2, 0.7, 9.7, 4.8, and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively. |
| M9747 | Lanifibranor | Lanifibranor (IVA-337) is a peroxisome proliferator-activated receptors (PPAR) agonist, with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively. |
| M29067 | Farglitazar | Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients. |
| M29032 | FK614 | FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes. |
| M28361 | Darglitazone | Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research. |
| M28316 | MHY908 | MHY908 is a potent dual agonist of PPARα and PPARγ. MHY908 also inhibits melanogenesis through inhibition of mushroom tyrosinase activity. |
| M28026 | DS-6930 | DS-6930 is a potent and selective agonist of PPARγ, with an EC50 of 41 nM. DS-6930 could robust reduce plasma glucose (PG), and with fewer PPARγ-related adverse effects than Rosiglitazone. DS-6930 can be used for the research of diabetes. |
| M21176 | Leriglitazone | Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) is a PPARγ agonist that provides high transcriptional potency by stabilizing the PPARγ (AF-2) coactivator binding surface and enhancing coactivator binding capacity. Leriglitazone (Hydroxypioglitazone) binds to PPARγC (LBD) with a Ki value of 1.2 μM and induces PPARγ (LBD) transcriptional efficiency with an EC50 of 680 nM. |
| M21025 | Balofloxacin Dihydrate | an agonist of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway |
| M20942 | Choline Fenofibrate | Choline fenofibrate is a newly developed choline salt of fenofibric acid, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist. |
| M18066 | 13-Oxo-9E,11E-octadecadienoic acid | 13-Oxo-9E,11E-octadecadienoic acid |
| M11286 | NXT629 | NXT629 is an effective, selective and competitive PPAR-α antagonist. The IC50 value of HUMAN PPARα is 77 nM, which is higher than that of other nuclear hormone receptors, such as PPARδ, PPARγ, Erβ, GR and TRβ, with IC50 value of 6.0, 15, respectively. 15.2, 32.5 and >100 μM. |
| M11283 | Inolitazone dihydrochloride | Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a PPARγ agonist with high affinity, activity dependent on PPARγ, inhibiting growth, IC50 is 0.8 nM. |
| M11282 | L-165041 | L-165041 is a cell-permeable PPARδ agonist with Ki values of 6 nM for PPARδ and about 730 nM for PPARγ, which can induce adipocyte differentiation in NIH-PPARδ cells. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
